Search
Search Constraints
You searched for: Author/Creator Besse, Benjamin Issue Volume 166(2022)Limit your search
- Besse, Benjamin [remove] 3
- Electronic journals 3
- Periodicals 3
- 616.994 2
- Cancer 2
- Cancer -- Periodicals 2
- Cancer -- Périodiques 2
- Neoplasms -- Periodicals 2
- Tumors 2
- 616.99424 1
- AE Adverse event -- BRAF B-RAF proto-oncogene serine/threonine kinase -- CI Confidence interval -- CTCAE Common Terminology Criteria for Adverse Events -- CTLA-4 Cytotoxic T-lymphocyte-associated protein 4 -- DLT Dose-limiting toxicity -- ECOG Eastern Cooperative Oncology Group -- EGFR Epidermal growth factor receptor -- GT GEFTREM -- ICI Immune checkpoint inhibitors -- ILD Interstitial lung disease -- irAE Immune-related adverse event -- IV Intravenous -- NR Not reached -- NSCLC Non-small cell lung cancer -- ORR Objective response rate -- OS Overall survival -- PD Progression disease -- PD-L1 Programmed death-ligand 1 -- PFS Progression-free survival -- Q4W Every 4 weeks -- Q12W Every 12 weeks -- RECIST Response Evaluation Criteria in Solid Tumours -- RP2D Recommended phase 2 dose -- SD Stable disease -- sCTLA-4 Soluble CTLA-4 -- TKI Tyrosine-kinase inhibitors -- TMB Tumour mutational burden -- TRAE Treatment-related adverse event -- TRM Resident memory T cells -- Vs Versus 1